<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN" "http://www.w3.org/TR/REC-html40/loose.dtd">
<html><body><html><body><section class="summaryOfFindings"><div class="section-header section-collapse-header" id="CD011990-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"><div class="section-header" id="CD011990-sec-0029"></div> <div class="table" id="CD011990-tbl-0001"> <a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading">
<span class="table-label">Summary of findings for the main comparison.</span>Â <span class="table-title">Keratinocyte growth factor (KGF) compared to placebo for preventing oral mucositis in adults with cancer receiving treatment</span>
</div>
<table class="summary-of-findings framed">
<tbody>
<tr class="table-header separated">
<td align="left" valign="top" colspan="7" rowspan="1" class="table-header"> <p><b> KGF compared to placebo for preventing oral mucositis in adults with cancer receiving treatment</b> </p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Patient or population:</b> adults<sup>**</sup> receiving treatment for cancer (see subgroup for treatment type)<br><b>Setting:</b> hospital<br><b>Intervention:</b> KGF<br><b>Comparison:</b> placebo </p> </td> </tr>
<tr class="table-header separated">
<td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Outcomes</b> </p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Relative effect<br> (95% CI)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Number of participants<br> (studies)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Quality of the evidence<br> (GRADE)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Comments</b> </p> </td> </tr>
<tr class="table-header separated">
<td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Risk with placebo</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Risk with KGF</b> </p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="1" rowspan="6" bgcolor="#ffffff"> <p>Oral mucositis (moderate + severe)</p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p>BMT/SCT after conditioning for haematological cancers</p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>RR 0.89<br> (0.80 to 0.99) </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>852<br> (6 studies) </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>ââââ<br> LOW<sup>1</sup></p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>There might be a benefit for KGF in this population</p> <p>NNTB = 11 (95% CI 6 to 112)</p> </td> </tr>
<tr class="table-header separated">
<td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>848 per 1000</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>755 per 1000<br> (678 to 839) </p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p>RT to head and neck with cisplatin/5FU</p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>RR 0.91<br> (0.83 to 1.00) </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>471<br> (3 studies) </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>ââââ<br> MODERATE<sup>2</sup></p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>There is probably a benefit for KGF in this population</p> <p>NNTB = 12 (95% CI 7 to â)</p> </td> </tr>
<tr class="table-header separated">
<td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>932 per 1000</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>848 per 1000<br> (773 to 932) </p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p>CT alone for mixed cancers</p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>RR 0.56<br> (0.45 to 0.70) </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>344<br> (4 studies) </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>ââââ<br> MODERATE<sup>3</sup></p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>It is likely that there is a benefit for KGF in this population</p> <p>NNTB = 4 (95% CI 3 to 6)</p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>631 per 1000</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>353 per 1000<br> (284 to 441) </p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="1" rowspan="6" bgcolor="#ffffff"> <p>Oral mucositis (severe)</p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p>BMT/SCT after conditioning for haematological cancers</p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>RR 0.85<br> (0.65 to 1.11) </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>852<br> (6 studies) </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>ââââ<br> LOW<sup>4</sup></p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>There might be a benefit for KGF in this population, but there is also some possibility of an increase in risk </p> <p>NNTB = 10 (95% CI 5 NNTB to 14 NNTH)</p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>677 per 1000</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>575 per 1000<br> (440 to 751) </p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p>RT to head and neck with cisplatin/5FU</p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>RR 0.79<br> (0.69 to 0.90) </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>471<br> (3 studies) </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>ââââ<br> HIGH </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>It is very likely that there is a benefit for KGF in this population</p> <p>NNTB = 7 (95% CI 5 to 15)</p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>700 per 1000</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>553 per 1000<br> (483 to 630) </p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p>CT alone for mixed cancers</p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>RR 0.30<br> (0.14 to 0.65) </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>263<br> (3 studies) </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>ââââ<br> LOW<sup>5</sup></p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>There might be a benefit for KGF in this population</p> <p>NNTB = 10 (95% CI 8 to 19)</p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>154 per 1000</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>46 per 1000<br> (22 to 100) </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Adverse events</p> </td> <td align="" valign="" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>Adverse events that were attributed to the study drugs rather than the cancer therapy were typically oralârelated or skinârelated. Events were mostly mild to moderate with very few incidences of serious events. However, reporting was poor and inconsistent, meaning that it was not appropriate to metaâanalyse data </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><sup>*</sup>The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br><sup>**</sup>Only 1 study in the subgroup BMT/SCT after conditioning for haematological cancers' included some children (but the median age of participants was 46 years). </p> <p><sup>***</sup>The number of people that would need to receive KGF in order to prevent 1 additional person from developing the outcome. Calculated as 1 divided by the absolute risk reduction (which is the control arm event rate minus the experimental arm event rate). NNTH means the number of people that would need to receive KGF to cause 1 additional person to develop the outcome. All decimal places have been rounded up to the nearest whole number (i.e. 6.1 = 7).<br><br><b>â:</b> infinity; <b>5FU:</b> fluorouracil; <b>BMT:</b> bone marrow transplantation; <b>CI:</b> confidence interval; <b>CT:</b> chemotherapy; <b>KGF:</b> keratinocyte growth factor; <b>NNTB:</b> number needed to treat to benefit<sup>***</sup>; <b>NNTH:</b> number needed to treat to harm; <b>RR:</b> risk ratio; <b>RT:</b> radiotherapy; <b>SCT:</b> stem cell transplantation. </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>GRADE Working Group grades of evidence</b> <br><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br><b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br><b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr>
</tbody>
<tfoot><tr>
<td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by 1 level for inconsistency (substantial heterogeneity: I<sup>2</sup> = 50% to 90%, P &lt; 0.1); downgraded 1 further level for publication bias as there are 2 references in <a href="./references#CD011990-bbs1-0003">Studies awaiting classification</a> that would be included in the conditioning/transplant subgroup, but the data are not available (<a href="./references#CD011990-bbs2-0068">NCT02313792</a>; <a href="./references#CD011990-bbs2-0073">Spielberger 2001</a>).<br><sup>2</sup>Downgraded by 1 level for inconsistency (substantial heterogeneity: I<sup>2</sup> = 50% to 90%, P &lt; 0.1).<br><sup>3</sup>Downgraded by 1 level for publication bias as there is 1 reference in <a href="./references#CD011990-bbs1-0003">Studies awaiting classification</a> that would be included in the chemotherapy alone subgroup, but the data are not available (<a href="./references#CD011990-bbs2-0066">NCT00393822</a>).<br><sup>4</sup>Downgraded by 1 level for inconsistency (substantial heterogeneity: I<sup>2</sup> = 50% to 90%, P &lt; 0.1); downgraded 1 further level for publication bias as there are 2 references in <a href="./references#CD011990-bbs1-0003">Studies awaiting classification</a> that would be included in the conditioning/transplant subgroup, but the data are not available (<a href="./references#CD011990-bbs2-0068">NCT02313792</a>; <a href="./references#CD011990-bbs2-0073">Spielberger 2001</a>); we did not downgrade for imprecision because, despite the confidence interval including a small chance of an increase in risk, it is a fairly narrow interval and a rating of 'very low quality' would seem an overly harsh rating for this body of evidence.<br><sup>5</sup>Downgraded by 1 level for imprecision (wide confidence interval, small sample size and low event rate); downgraded 1 further level for publication bias as there is 1 reference in <a href="./references#CD011990-bbs1-0003">Studies awaiting classification</a> that would be included in the chemotherapy alone subgroup, but the data are not available (<a href="./references#CD011990-bbs2-0066">NCT00393822</a>). </p> </div> </td> </tr></tfoot>
</table>
</div> <div class="table" id="CD011990-tbl-0002"> <a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading">
<span class="table-label">Summary of findings 2.</span>Â <span class="table-title">Granulocyteâmacrophage colonyâstimulating factor (GMâCSF) compared to placebo/no treatment for preventing oral mucositis in adults with cancer receiving treatment</span>
</div>
<table class="summary-of-findings framed">
<tbody>
<tr class="table-header separated">
<td align="left" valign="top" colspan="7" rowspan="1" class="table-header"> <p><b> GMâCSF compared to placebo/no treatment for preventing oral mucositis in adults with cancer receiving treatment</b> </p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Patient or population:</b> adults<sup>**</sup> receiving treatment for cancer (see subgroup for treatment type)<br><b>Setting:</b> hospital<br><b>Intervention:</b> GMâCSF<br><b>Comparison:</b> placebo/no treatment </p> </td> </tr>
<tr class="table-header separated">
<td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Outcomes</b> </p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Relative effect<br> (95% CI)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Number of participants<br> (studies)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Quality of the evidence<br> (GRADE)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Comments</b> </p> </td> </tr>
<tr class="table-header separated">
<td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Risk with placebo/no treatment</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Risk with GMâCSF</b> </p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="1" rowspan="4" bgcolor="#ffffff"> <p>Oral mucositis (moderate + severe)</p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p>BMT/SCT after conditioning for haematological cancers</p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>RR 0.94<br> (0.79 to 1.13) </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>109<br> (1 study) </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>ââââ<br> VERY LOW<sup>1</sup></p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>There is insufficient evidence to determine a benefit for GMâCSF in this population</p> <p>NNTB = 20 (95% CI 6 NNTB to 10 NNTH)</p> </td> </tr>
<tr class="table-header separated">
<td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>839 per 1000</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>789 per 1000<br> (663 to 948) </p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p>RT to head and neck</p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>RR 0.72<br> (0.49 to 1.06) </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>29<br> (1 study) </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>ââââ<br> VERY LOW<sup>2</sup></p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>There is insufficient evidence to determine a benefit for GMâCSF in this population</p> <p>NNTB = 4 (95% CI 3 NNTB to 14 NNTH)</p> </td> </tr>
<tr class="table-header separated">
<td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>929 per 1000</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>669 per 1000<br> (455 to 984) </p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="1" rowspan="6" bgcolor="#ffffff"> <p>Oral mucositis (severe)</p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p>BMT/SCT after conditioning for mixed cancers</p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>RR 0.74<br> (0.33 to 1.67) </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>235<br> (3 studies) </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>ââââ<br> LOW<sup>3</sup></p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>There is insufficient evidence to determine a benefit for GMâCSF in this population</p> <p>NNTB = 12 (95% CI 5 NNTB to 5 NNTH)</p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>347 per 1000</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>257 per 1000<br> (115 to 580) </p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p>RT to head and neck</p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>RR 0.31<br> (0.01 to 7.09) </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>29<br> (1 study) </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>ââââ<br> VERY LOW<sup>4</sup></p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>There is insufficient evidence to determine a benefit for GMâCSF in this population</p> <p>NNTB = 21 (95% CI 15 NNTB to 3 NNTH)</p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>71 per 1000</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>22 per 1000<br> (1 to 506) </p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p>CT alone for mixed cancers</p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>RR 0.59<br> (0.05 to 7.11) </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>65<br> (2 studies) </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>ââââ<br> VERY LOW<sup>5</sup></p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>There is insufficient evidence to determine a benefit for GMâCSF in this population</p> <p>NNTB = 5 (95% CI 3 NNTB to 2 NNTH)</p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>500 per 1000</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>295 per 1000<br> (25 to 1000) </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Adverse events</p> </td> <td align="" valign="" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>Adverse events that were attributed to the study drugs rather than the cancer therapy were typically bone pain, nausea, fever and headache. Events were not reported as being serious. Some studies did not report adverse events and 1 even reported that there were none. However, reporting was poor and inconsistent, meaning that it was not appropriate to metaâanalyse data </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><sup>*</sup>The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br><sup>**</sup>There were no studies conducted on children. </p> <p><sup>***</sup>The number of people that would need to receive GMâCSF in order to prevent 1 additional person from developing the outcome. Calculated as 1 divided by the absolute risk reduction (which is the control arm event rate minus the experimental arm event rate). NNTH means the number of people that would need to receive GMâCSF to cause 1 additional person to develop the outcome. All decimal places have been rounded up to the nearest whole number (i.e. 6.1 = 7).<br><br><b>BMT:</b> bone marrow transplantation; <b>CI:</b> confidence interval; <b>CT:</b> chemotherapy; <b>GMâCSF:</b> granulocyteâmacrophage colonyâstimulating factor; <b>NNTB:</b> number needed to treat to benefit<sup>***</sup>; <b>NNTH:</b> number needed to treat to harm; <b>RR:</b> risk ratio; <b>RT:</b> radiotherapy; <b>SCT:</b> stem cell transplantation. </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>GRADE Working Group grades of evidence</b> <br><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br><b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br><b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr>
</tbody>
<tfoot><tr>
<td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by 2 levels for imprecision (single study with a small sample size and the confidence interval includes a possible increase in risk that is of a similar magnitude to the possible reduction in risk); downgraded 1 further level for indirectness (single study so not widely generalisable).<br><sup>2</sup>Downgraded by 2 levels for imprecision (wide confidence interval and very small sample size); downgraded by 1 further level for high risk of performance bias; downgraded by 1 further level for indirectness (single study so not widely generalisable); downgraded by 1 further level for publication bias as there are 2 references in <a href="./references#CD011990-bbs1-0003">Studies awaiting classification</a> that would be included in the RT to head and neck subgroup, but the data are not currently available (<a href="./references#CD011990-bbs2-0061">Antonadou 1998</a>; <a href="./references#CD011990-bbs2-0065">NCT00293462</a>).<br><sup>3</sup>Downgraded by 2 levels for imprecision (small sample size and the confidence interval includes a possible increase in risk that is of a similar magnitude to the possible reduction in risk); downgraded by 1 further level for inconsistency (substantial heterogeneity: I<sup>2</sup> = 50% to 90%, P &lt; 0.1).<br><sup>4</sup>Downgraded by 2 levels for imprecision (extremely wide confidence interval incorporating both very large increase and reduction in risk, very small sample size and very low event rate); downgraded by 1 further level for high risk of performance bias; downgraded by 1 further level for indirectness (single study so not widely generalisable); downgraded by 1 further level for publication bias as there are 2 references in <a href="./references#CD011990-bbs1-0003">Studies awaiting classification</a> that would be included in the RT to head and neck subgroup, but the data are not currently available (<a href="./references#CD011990-bbs2-0061">Antonadou 1998</a>; <a href="./references#CD011990-bbs2-0065">NCT00293462</a>).<br><sup>5</sup>Downgraded by 2 levels for imprecision (extremely wide confidence interval incorporating both very large increase and reduction in risk and very small sample size); downgraded by 1 further level for high risk of performance bias; downgraded by 1 further level for inconsistency (substantial heterogeneity: I<sup>2</sup> = 50% to 90%, P &lt; 0.1). </p> </div> </td> </tr></tfoot>
</table>
</div> <div class="table" id="CD011990-tbl-0003"> <a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading">
<span class="table-label">Summary of findings 3.</span>Â <span class="table-title">Granulocyteâcolony stimulating factor (GâCSF) compared to placebo/no treatment for preventing oral mucositis in adults with cancer receiving treatment</span>
</div>
<table class="summary-of-findings framed">
<tbody>
<tr class="table-header separated">
<td align="left" valign="top" colspan="7" rowspan="1" class="table-header"> <p><b> GâCSF compared to placebo/no treatment for preventing oral mucositis in patients with cancer receiving treatment</b> </p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Patient or population:</b> adults<sup>**</sup> receiving treatment for cancer (see subgroup for treatment type)<br><b>Setting:</b> hospital <br><b>Intervention:</b> GâCSF<br><b>Comparison:</b> placebo/no treatment </p> </td> </tr>
<tr class="table-header separated">
<td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Outcomes</b> </p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Relative effect<br> (95% CI)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Number of participants<br> (studies)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Quality of the evidence<br> (GRADE)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Comments</b> </p> </td> </tr>
<tr class="table-header separated">
<td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Risk with placebo/no treatment</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Risk with GâCSF</b> </p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>Oral mucositis (moderate + severe)</p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p>CT alone for breast cancer</p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>RR 0.33<br> (0.12 to 0.95) </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>14<br> (1 study) </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>ââââ<br> VERY LOW<sup>1</sup></p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>There is very weak evidence that there might be a benefit for GâCSF in this population</p> <p>NNTB = 2 (95% CI 2 to 20)</p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>1000 per 1000</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>330 per 1000<br> (120 to 950) </p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>Oral mucositis (severe)</p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p>RT to head and neck</p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>RR 0.37<br> (0.15 to 0.87) </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>54<br> (2 studies) </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>ââââ<br> LOW<sup>2</sup></p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>There is weak evidence that there might be a benefit for GâCSF in this population</p> <p>NNTB = 3 (95% CI 3 to 15)</p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>519 per 1000</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>192 per 1000<br> (78 to 451) </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Adverse events</p> </td> <td align="" valign="" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>There was limited evidence of adverse events for GâCSF. 2 of the 6 studies did not report adverse events. There were low rates of mild to moderate events, the most common of which appeared to be bone pain. However, reporting was poor and inconsistent, meaning that it was not appropriate to metaâanalyse data </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><sup>*</sup>The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br><sup>**</sup>There were no studies conducted on children. </p> <p><sup>***</sup>The number of people that would need to receive GâCSF in order to prevent 1 additional person from developing the outcome. Calculated as 1 divided by the absolute risk reduction (which is the control arm event rate minus the experimental arm event rate). NNTH means the number of people that would need to receive GâCSF to cause 1 additional person to develop the outcome. All decimal places have been rounded up to the nearest whole number (i.e. 6.1 = 7).<br><br><b>CI:</b> confidence interval; <b>CT:</b> chemotherapy; <b>GâCSF:</b> granulocyteâcolony stimulating factor; <b>NNTB:</b> number needed to treat to benefit<sup>***</sup>; <b>NNTH:</b> number needed to treat to harm; <b>RR:</b> risk ratio; <b>RT:</b> radiotherapy. </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>GRADE Working Group grades of evidence</b> <br><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br><b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br><b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr>
</tbody>
<tfoot><tr>
<td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by 2 levels for imprecision (wide confidence interval and very small sample size); downgraded by 1 further level for high risk of performance bias; downgraded by 1 further level for indirectness (single study so not widely generalisable).<br><sup>2</sup>Downgraded by 2 levels for imprecision (wide confidence interval and very small sample size). </p> </div> </td> </tr></tfoot>
</table>
</div> </section></section></body></html></body></html>
